BCI HomeNewsGeneral News

General News

Print
PDF

Dr Thorsten Hagemann talks about the tumour microenvironment on eCancer.TV

on 28 November 2011.

Thorsten_hagemann_eCancer_TV

Dr Thorsten Hageman talks to Professor Gordon McVie at the NCRI about the microenvironment.

 

Dr Hagemann discusses how to address the clinical questions but also how to target specific cells, which are not malignant in the tumour microenvironment.

Dr Hageman goes on to explain why Ipilimumab is such good news for treatment. He talks about how to target the myeloid suppression system, with regard to specific signalling pathways and specific cell surface markers. Dr Hageman ends the interview with a call for a combined approach targeting innate immunity and adaptive immunity with Ipilimumab.

→Click here to watch video interview

 


Print
PDF

BCI researchers awarded Cancer Research-UK grant for new high tech gene projects.

on 18 November 2011.

cr-uk_gene_project_award      

cruklogo

Project tile: Molecular basis of transformation of follicular lymphoma to aggressive diffuse large B cell lymphoma

The study, which is one of just 9 funded projects across all cancers, will be completed over the next year by Dr Jude Fitzgibbon and Dr Silvia Montoto in the Centre for Haemato-Oncology and Dr Claude Chelala in the Centre for Molecular Oncology.

Follicular lymphoma is an incurable indolent B cell malignancy representing 25% of all Non-Hodgkin¹s Lymphomas. Although the median overall survival is 10-12 years, transformation to aggressive lymphoma occurs in 30% of patients and has a particularly poor outcome, with a survival of less than 18 months. This is the critical clinical event in the course of a patient¹s disease and there is no single or group of genetic lesions identified that can account for this shift to aggressive lymphoma. Cancer Research UK, as part of their Genomics Sequencing Initiative, are funding a whole genome analysis of follicular and transformation biopsies from 6 patients to identify the mutational changes associated with this poor outcome group.

Print
PDF

Dr Athina-Myrto Chioni awarded the 2011 Papanicolaou prize

on 12 November 2011.

Athina-Myrto_Chioni           

Hellenic_Medical_Society

Dr Athina-Myrto Chioni was awarded the 2011 Papanicolaou prize from the Hellenic Medical Society of Great Britain, for her presentation on "FGFR1 cleavage and nuclear translocation regulates breast cancer cell behaviour"

Dr Chioni is a postdoctoral research assistant working with Dr Richard Grose in the Centre for Tumour Biology. Her project is on 'a novel role of FGFR1 signalling in breast cancer'.

Recent publications:

  • Chioni AM, Shao D, Grose R, Djamgoz MB (2010). Protein kinase A and regulation of neonatal     Nav1.5 expression in human breast cancer cells: activity-dependent positive feedback and cellular migration. Int J Biochem Cell Biol. 42(2):346-58. [PMID:19948241]
  • Chioni AM, Grose R. Negative regulation of fibroblast growth factor 10 (FGF-10) by polyoma enhancer activator 3 (PEA3). (2009). Eur J Cell Biol. 88(7):371-84. [PMID:19410332]
  • Chioni A-M, Grose R. (2008). Organotypic modelling as a means of investigating epithelial-stromal interactions during tumourigenesis. Fibrogenesis & Tissue Repair. 1:8 [PMID:19077226]

More Articles...